Finance
Skincare Firm Galderma Posts 25.5% Sales Jump Driven by US Market
Published by Global Banking & Finance Review®
Posted on April 23, 2026
1 min readLast updated: April 23, 2026
Add as preferred source on GoogleQuick Summary
Swiss skincare firm Galderma reported a 25.5% surge in first‑quarter net sales (constant currency) to US $1.473 billion, driven by a 41.5% jump in U.S. sales. The company expects the impact of U.S. tariffs in 2026 to remain manageable and reaffirmed full‑year guidance.
Galderma Achieves 25.5% Sales Increase in Q1, US Market Fuels Surge
Galderma's Q1 Financial Performance and Market Outlook
Strong Sales Growth Driven by US Market
ZURICH, April 23 (Reuters) - Swiss skincare firm Galderma on Thursday said first-quarter sales jumped 25.5% in constant-currency terms to $1.47 billion, and signalled it would be able to manage the impact of U.S. tariffs in 2026.
The Zug-based company's results showed that brisk business in the United States powered growth in the January-March period, with sales there leaping 41.5% year-on-year.
Company Confidence Amid Volatile Environment
"Based on the strong start to the year, the guidance is increasingly being de-risked with confidence to navigate a volatile environment," Galderma said in a statement.
Tariff Exposure and Guidance for 2024
Galderma, which was listed on the Swiss stock exchange just over two years ago, said its exposure to U.S. tariffs is expected to remain "manageable" this year.
Alongside tariffs assumed for its Sculptra and Restylane injectables, the firm's confirmed full-year guidance also factors in the expected impact of a recent U.S. announcement on imports of pharmaceuticals and pharmaceutical ingredients.
(Writing by Dave GrahamEditing by Ludwig Burger)
Key Takeaways
- •Q1 net sales rose 25.5% at constant currency to US $1.473 billion, propelled by a 41.5% increase in U.S. sales (galderma.com)
- •Growth was broad‑based across categories: Injectable Aesthetics +13.1%, Dermatological Skincare +17.0%, Therapeutic Dermatology +71.3%, notably Nemluvio sales (galderma.com)
- •Galderma confirmed full‑year 2026 guidance (17–20% net‑sales growth; ~26% Core EBITDA margin) and expects exposure to U.S. tariffs, including those on Sculptra, Restylane and broader pharma imports, to remain manageable (galderma.com)
References
Frequently Asked Questions about Skincare firm Galderma posts 25.5% sales jump driven by US market
1What was Galderma's Q1 sales growth in 2024?
Galderma's first-quarter sales grew by 25.5% in constant-currency terms to $1.47 billion.
2Which market contributed most to Galderma's recent sales increase?
The United States market contributed most, with sales climbing 41.5% year-on-year.
3How does Galderma plan to handle U.S. tariffs in 2026?
Galderma signaled its exposure to U.S. tariffs will remain manageable and is included in its risk assessments and guidance.
4Which products are affected by the US tariffs for Galderma?
Sculptra and Restylane injectables are among the products affected by US tariffs.
5When was Galderma listed on the Swiss stock exchange?
Galderma was listed on the Swiss stock exchange just over two years ago.
